Recombinant human Noggin protein (Active) is a Human Full Length protein, in the 28 to 232 aa range, expressed in HEK 293, with >=95% purity, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE, FuncS, MS, HPLC, Cell Culture.
Q H Y L H I R P A P S D N L P L V D L I E H P D P I F D P K E K D L N E T L L R S L L G G H Y D P G F M A T S P P E D R P G G G G G A A G G A E D L A E L D Q L L R Q R P S G A M P S E I K G L E F S E G L A Q G K K Q R L S K K L R R K L Q M W L W S Q T F C P V L Y A W N D L G S R F W P R Y V K V G S C F S K R S C S V P E G M V C K P S K S V H L T V L R W R C Q R R G G Q R C G W I P I Q Y P I I S E C K C S C
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Application FuncS | Reactivity Reacts | Dilution info - | Notes - |
Application MS | Reactivity Reacts | Dilution info - | Notes - |
Application HPLC | Reactivity Reacts | Dilution info - | Notes - |
Application Cell Culture | Reactivity Reacts | Dilution info - | Notes - |
Inhibitor of bone morphogenetic proteins (BMP) signaling which is required for growth and patterning of the neural tube and somite. Essential for cartilage morphogenesis and joint formation. Inhibits chondrocyte differentiation through its interaction with GDF5 and, probably, GDF6 (PubMed:21976273, PubMed:26643732).
Noggin, NOG
Recombinant human Noggin protein (Active) is a Human Full Length protein, in the 28 to 232 aa range, expressed in HEK 293, with >=95% purity, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE, FuncS, MS, HPLC, Cell Culture.
ED50 for this effect is ≤65.37 ng/ml, corresponding to a specific activity of 1.52 x 104 units/mg.
pH: 7.4
Constituents: 10% Trehalose, 0.727% Dibasic monohydrogen potassium phosphate, 0.248% Potassium phosphate monobasic
>=95% Purity by HPLC
Inhibitor of bone morphogenetic proteins (BMP) signaling which is required for growth and patterning of the neural tube and somite. Essential for cartilage morphogenesis and joint formation. Inhibits chondrocyte differentiation through its interaction with GDF5 and, probably, GDF6 (PubMed:21976273, PubMed:26643732).
Belongs to the noggin family.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Noggin also known as noggin protein is a secreted glycoprotein with a mass of approximately 26 kDa. It antagonizes bone morphogenetic proteins (BMPs) by directly binding them preventing their interaction with receptors. This binding inhibits the signaling pathway which affects cellular processes such as differentiation growth and apoptosis. Noggin expresses prominently in embryonic tissues and in tissues undergoing differentiation particularly in the neural tube notochord and developing articular cartilage. The expression pattern suggests its importance during critical phases of development and tissue patterning.
Noggin functions as an essential regulator in embryonic development sculpting tissues by inhibiting BMP activity. It does not work alone but functions as part of a complex regulatory network involving other BMP antagonists. By inhibiting BMPs Noggin plays an important role in neural tube closure limb formation and somite development. Noggin's activities help modulate the balance between proliferation and differentiation in these contexts allowing for proper structural formation during embryogenesis.
Noggin operates mainly within the TGF-beta/BMP signaling pathway serving as a critical modulator. Inhibiting BMP through Noggin affects downstream targets connecting it to other signaling proteins like SMADs which mediate transcriptional responses. This control enables Noggin to indirectly regulate Wnt signaling as well showing its impact on various developmental stages and processes. Its influence on these pathways indicates Noggin’s importance in maintaining cellular homeostasis during growth and morphogenesis.
Noggin relates to conditions such as fibrodysplasia ossificans progressiva and cartilage-related abnormalities. Mutations or dysregulation of noggin protein can disrupt normal BMP signaling leading to aberrant skeletal development and calcification. This disruption often involves interactions with other proteins like BMP4 revealing Noggin's critical role in maintaining bone and cartilage integrity. Targeting noggin pathway components may provide therapeutic potential for addressing such conditions.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Functional analysis of ab281817.
Fully biologically active determined by its ability to inhibit BMP-4 induced alkaline phosphatase activity in ATDC5 cells.
ED50 for this effect is ≤65.37 ng/ml, corresponding to a specific activity of 1.52 x 104 units/mg.
Cell based assay testing is performed on the first lot of protein only and is provided as a reference for protein activity; subsequent lots of protein must pass all biophysical quality control parameters that meet the same parameters as the first lot.
Lot: GR3387043-1
SDS-PAGE analysis of ab281817.
Mass determination by ESI-TOF.
Predicted MW is 23104.64 Da. (+/- 10 Da by ESI-TOF). Observes MW is 23106.53 Da. Additional masses at 23382.04 is due to residual O-glycans.
HPLC analysis of ab281817.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com